FIELD: organic chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to the field of organic chemistry and pharmaceutics; it is aimed at the treatment of hepatitis C. A compound of the presented formula is disclosed. In addition, a pharmaceutical composition for the treatment or prevention of HCV, containing effective amount of the specified compound in a pharmaceutically acceptable carrier, as well as the use of the compound by cl. 1 for the treatment of a hepatitis C virus (HCV) in a human are disclosed.
EFFECT: group of inventions provides effective treatment of hepatitis C.
2 cl, 26 dwg, 37 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF VIRAL DISEASES | 2009 |
|
RU2519947C2 |
| ANTIVIRAL COMPOSITION AND METHOD OF ITS APPLICATION | 2017 |
|
RU2650610C1 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| GASTRO-RESISTANT DOSAGE FORMS FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE | 2018 |
|
RU2812901C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | 2006 |
|
RU2440822C2 |
| PRODRUG OF POLYMERASE NS5B HCV INHIBITOR, METHOD FOR ITS PREPARATION AND APPLICATION | 2017 |
|
RU2644156C1 |
| PRODRUG BASED ON URIDINE PHOSPHORAMIDE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINE | 2017 |
|
RU2740760C2 |
| TREATMENT OF HYPERKINETIC MOTOR DISORDERS | 2015 |
|
RU2753740C2 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
